6 Result(s)

Article

Real-World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis: Safety of EGFR-TKI Rechallenge (Osi-risk Study TORG-TG2101)

Although osimertinib is a promising therapeutic agent for advanced epidermal growth factor receptor (EGFR) mutation-positive lung cancer, the incidence of pneumonitis is particularly high among Japanese patients ...

Naoya Nishioka, Hisao Imai, Masahiro Endo, Akifumi Notsu… in Targeted Oncology (2024)

Article

Rationale and protocol design of a phase II study of first-line osimertinib treatment for patients with poor performance status and EGFR mutation-positive non-small cell lung cancer (OPEN/TORG2040)

Cancer chemotherapy indications for patients with poor performance status and advanced lung cancer are limited. Molecular targeted drugs, including epidermal growth factor receptor (EGFR)-tyrosine kinase inhib...

Tomoya Fukui, Jiichiro Sasaki, Satoshi Igawa, Akiko Kada, Toshiki I. Saito… in BMC Cancer (2022)

Article

Efficacy and risk of cytotoxic chemotherapy in extensive disease-small cell lung cancer patients with interstitial pneumonia

Small cell lung cancer (SCLC) is characterized by a high propensity for metastases and a poor prognosis irrespective of high sensitivity for initial chemotherapy. Although interstitial pneumonia (IP) is one of...

Masayuki Shirasawa, Tomoya Fukui, Seiichiro Kusuhara, Yasuhiro Hiyoshi… in BMC Cancer (2019)

Article

Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016

Preclinical studies have demonstrated that docetaxel and bevacizumab may act synergistically by decreasing endothelial cell proliferation and preventing circulating endothelial progenitor mobilization. The obj...

Satoshi Ikeda, Terufumi Kato, Takashi Ogura, Akimasa Sekine, Tsuneyuki Oda… in BMC Cancer (2018)

Article

Prognostic factors affecting the risk of thoracic progression in extensive-stage small cell lung cancer

The efficacy of combined modality therapy is evaluated for patients with extensive-stage (ES) small cell lung cancer (SCLC). This study evaluated prognostic factors affecting the risk of thoracic progression i...

Tomoya Fukui, Michiko Itabashi, Mikiko Ishihara, Yasuhiro Hiyoshi… in BMC Cancer (2016)

Article

Erratum to: Evaluation of S-1 as third- or further-line chemotherapy in advanced non-small-cell lung cancer

Akira Ono, Tateaki Naito, Haruyasu Murakami… in International Journal of Clinical Oncology (2010)